CN108774219A - 抑制pd-1/pd-l1的小分子化合物及其用途 - Google Patents
抑制pd-1/pd-l1的小分子化合物及其用途 Download PDFInfo
- Publication number
- CN108774219A CN108774219A CN201810475692.3A CN201810475692A CN108774219A CN 108774219 A CN108774219 A CN 108774219A CN 201810475692 A CN201810475692 A CN 201810475692A CN 108774219 A CN108774219 A CN 108774219A
- Authority
- CN
- China
- Prior art keywords
- substituted
- compound
- ester
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 40
- 108010074708 B7-H1 Antigen Proteins 0.000 title claims abstract description 22
- 102000008096 B7-H1 Antigen Human genes 0.000 title claims abstract 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 15
- 150000002148 esters Chemical class 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 11
- 239000003112 inhibitor Substances 0.000 claims abstract description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- -1 nitro, carboxyl Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000016847 malignant urinary system neoplasm Diseases 0.000 claims description 2
- 201000011682 nervous system cancer Diseases 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 201000004435 urinary system cancer Diseases 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 125000003375 sulfoxide group Chemical group 0.000 claims 1
- 238000012216 screening Methods 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 7
- 201000001441 melanoma Diseases 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 4
- 230000008485 antagonism Effects 0.000 abstract description 3
- 238000005094 computer simulation Methods 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 230000004907 flux Effects 0.000 abstract description 3
- 238000003041 virtual screening Methods 0.000 abstract description 3
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 230000009257 reactivity Effects 0.000 abstract 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 21
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 20
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101100499351 Chlorobaculum tepidum (strain ATCC 49652 / DSM 12025 / NBRC 103806 / TLS) lpd gene Proteins 0.000 description 1
- 208000001154 Dermoid Cyst Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- MTFJSAGADRTKCI-UHFFFAOYSA-N N-(pyridin-2-ylmethylidene)hydroxylamine Chemical compound ON=CC1=CC=CC=N1 MTFJSAGADRTKCI-UHFFFAOYSA-N 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了化合物或其药学上可以接受的盐或酯或溶剂化合物在制备PD‑1/PD‑L1小分子抑制剂药物中的用途。本发明通过计算机模拟虚拟筛选出化合物库中具有潜在活性的候选分子,运用均相时间分辨荧光技术,对候选分子拮抗PD‑1/PD‑L1结合情况进行高通量筛选,选择活性较好的化合物进行小鼠黑色素瘤B16‑F10植瘤实验,确定本发明筛选的化合物具有抗肿瘤活性。
Description
技术领域
本发明涉及一类化合物或其药学上可以接受的盐或酯或溶剂化合物在制备PD-1/PD-L1抑制剂药物中的用途,属于医药领域。
背景技术
程序性细胞死亡蛋白1(programmed cell deathprotein 1,PD-1)是一种表达于T细胞,并可下调免疫系统功能的Ⅰ型跨膜蛋白,由288个氨基酸构成,包括胞外段的IgV区,跨膜段以及胞内部分。该蛋白的胞内段在免疫受体酪氨酸抑制基序和免疫受体酪氨酸转换基序上存在两个关键的磷酸化位点,其在PD-1发挥抑制T细胞信号转导的过程中起了重要作用。PD-1的天然结合配体为程序性细胞死亡蛋白配体1(programmed death-ligand 1, PD-L1)和程序性细胞死亡蛋白配体2(programmed death-ligand 2,PD-L2),与配体结合后可抑制T细胞产生的免疫应答,降低相关细胞因子的产生。研究表明,PD-1/PD-L1靶点在肿瘤、自身免疫性疾病以及移植排斥等方面均有重要作用。当肿瘤发生时,组织细胞表面的PD-L1表达量上调,产生抑制 T细胞激活的信号,从而介导肿瘤逃逸的发生。目前PD-1/PD-L1抑制剂的开发主要集中在单克隆抗体领域,已有派姆单抗(Pembrolizumab)、纳武单抗(Nivolumab)、阿特珠单抗(Atezolizumab)等药物上市,可用于治疗黑色素瘤、转移性非小细胞肺癌、转移性头颈鳞状上皮细胞癌等恶性肿瘤,并且治疗效果显著。与抗体药物良好的发展现况相比,小分子药物的研发却进展缓慢。因此,亟需一类小分子化合物,用于制备治疗恶性肿瘤的药物。
发明内容
本发明的目的在于提供一类化合物或其药学上可以接受的盐或酯或溶剂化合物,制备PD-1/PD-L1抑制剂药物,用于治疗恶性肿瘤。
本发明结合PD-1/PD-L1共晶结构,通过计算机模拟虚拟筛选出化合物库中具有潜在活性的候选分子,运用均相时间分辨荧光技术,对候选分子拮抗PD-1/PD-L1结合情况进行高通量筛选,选择活性较好的化合物进行深入研究,待测样品库购自美国ChemDiv公司高通量筛选化合物库。
为实现上述目的,本发明采用如下技术方案:
式(Ⅰ)的化合物或其药学上可以接受的盐或酯或溶剂化合物在制备 PD-1/PD-L1小分子抑制剂药物中的用途,
其中,R1为
中的一种;
R2为氢、卤素、1~6个碳的取代或非取代的烷基(如甲基、乙基)、取代或非取代的苄基、取代或非取代的杂芳基亚甲基(如吡啶亚甲基、四氟吡啶亚甲基)、1~6个碳的取代或非取代的烷基氧基(如甲氧基)、氰基(如乙腈)、硝基(如甲硝基)、羧基、酯基(如甲酯基)、氨基、取代氨基(如甲氨基)、羟基、酰胺(如甲酰胺)、磺酰胺(如甲磺酰胺)、取代或非取代的苯甲酰基(如四氟苯甲酰基)、取代或非取代的杂芳基甲酰基(如四氟吡啶)、取代或非取代的苯磺酰基(如四氟苯磺酰基)、取代或非取代的芳基或杂芳基(如三氯苯环)、1~6个碳的烷基砜基或1~6个碳的烷基亚砜基 (如甲砜基)、ArCO(CH2)m-、Ar(CH2)mCO-、ArCOCO-、ArCO(CH2)mCO-、 ArCONH(CH2)m-、ArCOO(CH2)m-、Ar(CH2)mOOC-或Ar(CH2)mNHOC-,其中,Ar为取代或非取代的芳基或杂芳基,m=1~6。
进一步,式(Ⅰ)的化合物或其药学上可以接受的盐或酯或溶剂化合物用于开发以PD-1/PD-L1为靶点的小分子抑制剂。
进一步,式(Ⅰ)的化合物或其药学上可接受的盐或酯或溶剂化合物在制备预防和治疗抗肿瘤药物中的用途。
进一步,所述肿瘤包括血液癌症、神经系统癌症、胃肠癌、食道癌、泌尿系统癌症、肺癌、肝癌和皮肤癌。
进一步,一种药物组合物,含有式(Ⅰ)的化合物或其药学上可接受的盐或酯或溶剂化物,和药学上可接受的载体。
进一步,所述药物组合物为片剂、胶囊、颗粒剂、散剂、糖浆剂、口服液或注射剂。
本发明的有益效果是:本发明通过计算机模拟虚拟筛选出化合物库中具有潜在活性的候选分子,运用均相时间分辨荧光技术,对候选分子拮抗 PD-1/PD-L1结合情况进行高通量筛选,选择活性较好的化合物进行小鼠黑色素瘤B16-F10植瘤实验,确定本发明筛选的化合物具有抗肿瘤活性。
具体实施方式
以下结合实施例对本发明做进一步的详细描述,所举实例只用于解释本发明,并非用于限定本发明的范围。
实施例1
本发明采用商业化PD-1/PD-L1抑制剂筛选试剂盒,其是基于均相时间分辨荧光技术(Homogeneous Time-Resolved Fluorscence,HTRF)开发的高通量试剂盒。主要依靠受激发的稀土金属螯合物释放能量转移到发光基团而产生检测信号。实验中带有标签1的Tag1-PD-1会与带有标签2的 Tag2-PD-L1结合,加入带有螯合了Eu3+的Tag1抗体以及带有发光基团XL665 的Tag2抗体后,抗体将与各自的目标蛋白结合,在没有阻断剂存在的情况下,PD-1与PD-L1相互结合,两个荧光集团相互靠近,发生荧光共振能量转移,一部分能量将从荧光供体Eu3+基团转移至荧光受体XL665基团,并在665nm处产生荧光,而未被转移的能量将在620nm处发出荧光,此信号将作为背景信号而存在。当拮抗剂存在时,PD-1/PD-L1的结合会被抑制,荧光基团之间距离增加则会使得能量转移失败,荧光信号减弱。利用荧光信号强弱,即可反应出化合物对于PD1/PD-L1结合作用的抑制效果。
实验设计如表1所示:
表1实验组别设计
表1所用蛋白及抗体均为试剂盒内试剂,经试剂盒内相应的溶液溶解后配置成工作液后使用。操作时每孔反应体系中溶剂二甲亚砜(DMSO)的终浓度为0.1%,PD-1的反应终浓度为50nM,PD-L1的反应终浓度为5nM。化合物初筛浓度为10μM。采用Graphpad Prism5.0统计分析软件计算活性化合物IC50。
操作步骤如下:
阴性对照、阳性对照和实验组均设置3个重复。
(1)阴性对照在反应孔中加入6μL稀释液,阳性对照在反应孔中加入 2μL稀释液和4μLPD-L1-Tag1,实验组在反应孔中加入2μL化合物和4μL PD-L1-Tag1;
(2)在每个孔中分别加入4μLPD-1-Tag2;
(3)在每个孔中分别加入4μLPD-L1蛋白;
(4)在每个孔中分别加入4μLPD-1蛋白;
(5)室温避光孵育15min;
(6)分别在每个孔中依次加入5μL anti-Tag1-Eu3+和5μL anti-Tag2-XL665;
(7)室温避光孵育1h;
(8)使用Perkin Elmer Envision进行荧光信号检测。
筛选得到的PD-1/PD-L1小分子抑制剂的结构通式如下:
筛选得到的PD-1/PD-L1小分子抑制剂的IC50如表2所示。
表2筛选得到的PD-1/PD-L1小分子抑制剂的IC50
实施例2化合物M355-0148、M355-0149、M355-0152对小鼠黑色素瘤体内的抑瘤效应
Ⅰ、细胞培养
B16-F10细胞在1640完全培养基(含10%FBS)中培养,待细胞处于对数生长期,生长融合度为80%~90%时,胰酶消化传代。
Ⅱ、小鼠黑色素瘤B16-F10植瘤实验
(1)小鼠分组
取生长状态基本一致的小鼠共24只,分为4组,包括对照组、M355-0148、 M355-0149、M355-0152组;以PBS为空白对照,以M355-0148、M355-0149、 M355-0152为药物,给药剂量为20mg/kg,灌胃给药。
(2)小鼠皮内接种黑色素瘤B16-F10细胞
①麻醉小鼠:将装有黑色素瘤B16-F10细胞的EP管颠倒混匀6次,吸取细胞培养液至0.4ml;
②给每只小鼠的两边腹股沟皮内注射B16F10细胞,每边100μl。
(3)小鼠给药方法
植瘤当天记为D0天,D3天开始给药,灌胃给药,20mg/kg/day。D9天开始,用异氟烷将小鼠麻醉,称重,用游标卡尺测量左右两边肿瘤大小。待肿瘤体积约为2000mm3时,停止给药,处死小鼠,终止动物实验。
各组小鼠肿瘤体积比较结果如表3所示,表明本发明筛选得到的化合物M355-0148、M355-0149、M355-0152对肿瘤具有抑制作用。
表3各组小鼠肿瘤体积
注:所有实验结果均用Mean±SD表示。
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (6)
1.式(Ⅰ)的化合物或其药学上可接受的盐或酯或溶剂化合物在制备PD-1/PD-L1小分子抑制剂药物中的用途,
其中,R1为
中的一种;
R2为氢、卤素、1~6个碳的取代或非取代的烷基、取代或非取代的苄基、取代或非取代的杂芳基亚甲基、1~6个碳的取代或非取代的烷基氧基、氰基、硝基、羧基、酯基、氨基、取代氨基、羟基、酰胺、磺酰胺、取代或非取代的苯甲酰基、取代或非取代的杂芳基甲酰基、取代或非取代的苯磺酰基、取代或非取代的芳基或杂芳基、1~6个碳的烷基砜基或1~6个碳的烷基亚砜基、ArCO(CH2)m-、Ar(CH2)mCO-、ArCOCO-、ArCO(CH2)mCO-、ArCONH(CH2)m-、ArCOO(CH2)m-、Ar(CH2)mOOC-或Ar(CH2)mNHOC-,其中,Ar为取代或非取代的芳基或杂芳基,m=1~6。
2.权利要求1所述的化合物或其药学上可以接受的盐或酯或溶剂化合物用于开发以PD-1/PD-L1为靶点的小分子抑制剂。
3.权利要求1所述的化合物或其药学上可接受的盐或酯或溶剂化合物在制备预防和治疗抗肿瘤药物中的用途。
4.根据权利要求3所述的化合物或其药学上可接受的盐或酯或溶剂化合物在制备预防和治疗抗肿瘤药物中的用途,其特征在于,所述肿瘤包括血液癌症、神经系统癌症、胃肠癌、食道癌、泌尿系统癌症、肺癌、肝癌和皮肤癌。
5.一种药物组合物,其特征在于,含有权利要求1所述的化合物或其药学上可接受的盐或酯或溶剂化物,和药学上可接受的载体。
6.根据权利要求5所述的一种药物组合物,其特征在于,所述药物组合物为片剂、胶囊、颗粒剂、散剂、糖浆剂、口服液或注射剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810475692.3A CN108774219B (zh) | 2018-05-17 | 2018-05-17 | 抑制pd-1/pd-l1的小分子化合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810475692.3A CN108774219B (zh) | 2018-05-17 | 2018-05-17 | 抑制pd-1/pd-l1的小分子化合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108774219A true CN108774219A (zh) | 2018-11-09 |
CN108774219B CN108774219B (zh) | 2021-05-04 |
Family
ID=64027401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810475692.3A Expired - Fee Related CN108774219B (zh) | 2018-05-17 | 2018-05-17 | 抑制pd-1/pd-l1的小分子化合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108774219B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110491455A (zh) * | 2019-07-22 | 2019-11-22 | 广州中医药大学(广州中医药研究院) | 地骨皮乙素在制备抗肿瘤药物中的应用 |
CN112979532A (zh) * | 2021-05-20 | 2021-06-18 | 中国药科大学 | 邻苯二甲酰亚胺类化合物、制备方法和应用 |
CN113493469A (zh) * | 2020-03-18 | 2021-10-12 | 成都倍特药业股份有限公司 | 可作为免疫调节剂的化合物、其制备方法和应用 |
WO2022166991A1 (zh) * | 2021-02-08 | 2022-08-11 | 南京明德新药研发有限公司 | 吲哚啉类化合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017118762A1 (en) * | 2016-01-08 | 2017-07-13 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
CN107087409A (zh) * | 2014-09-19 | 2017-08-22 | 吕衍达 | 苯并杂环化合物及其应用 |
CN107365361A (zh) * | 2017-08-21 | 2017-11-21 | 中国药科大学 | 与pd‑l1结合的重复域锚定蛋白及其用途 |
-
2018
- 2018-05-17 CN CN201810475692.3A patent/CN108774219B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107087409A (zh) * | 2014-09-19 | 2017-08-22 | 吕衍达 | 苯并杂环化合物及其应用 |
WO2017118762A1 (en) * | 2016-01-08 | 2017-07-13 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
CN107365361A (zh) * | 2017-08-21 | 2017-11-21 | 中国药科大学 | 与pd‑l1结合的重复域锚定蛋白及其用途 |
Non-Patent Citations (1)
Title |
---|
潘佳佳等: ""PD-1/PD-Ls信号通路及其抗体在肿瘤治疗中的应用"", 《中国药科大学学报》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110491455A (zh) * | 2019-07-22 | 2019-11-22 | 广州中医药大学(广州中医药研究院) | 地骨皮乙素在制备抗肿瘤药物中的应用 |
CN110491455B (zh) * | 2019-07-22 | 2023-01-24 | 广州中医药大学(广州中医药研究院) | 地骨皮乙素在制备抗肿瘤药物中的应用 |
CN113493469A (zh) * | 2020-03-18 | 2021-10-12 | 成都倍特药业股份有限公司 | 可作为免疫调节剂的化合物、其制备方法和应用 |
WO2022166991A1 (zh) * | 2021-02-08 | 2022-08-11 | 南京明德新药研发有限公司 | 吲哚啉类化合物 |
CN112979532A (zh) * | 2021-05-20 | 2021-06-18 | 中国药科大学 | 邻苯二甲酰亚胺类化合物、制备方法和应用 |
WO2022242322A1 (zh) * | 2021-05-20 | 2022-11-24 | 中国药科大学 | 邻苯二甲酰亚胺类化合物、制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108774219B (zh) | 2021-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108774219A (zh) | 抑制pd-1/pd-l1的小分子化合物及其用途 | |
ES2802296T3 (es) | Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK | |
Ma et al. | Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts | |
CN103874689B (zh) | Akt抑制剂化合物和威罗菲尼的组合及使用方法 | |
CN101824029A (zh) | 酪氨酸激酶不可逆抑制剂、其药物组合物及其用途 | |
CN110088210A (zh) | 与酪氨酸激酶抑制剂结合使用的癌细胞增敏剂和增敏方法 | |
JP2008514726A (ja) | ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法 | |
Yuan et al. | Discovery of new 4-indolyl quinazoline derivatives as highly potent and orally bioavailable P-glycoprotein inhibitors | |
CN102311449B (zh) | 棉酚衍生物在制备抗肿瘤药物中的应用 | |
CN105985323A (zh) | 新型表皮生长因子受体抑制剂及其应用 | |
Wei et al. | Synthesis and anti-tumor activity of [1, 4] dioxino [2, 3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2 | |
Fan et al. | Discovery of Dioxino [2, 3-f] quinazoline derivative VEGFR-2 inhibitors exerting significant antipro-liferative activity in HUVECs and mice | |
Yu et al. | Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase | |
Wei et al. | A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer | |
CN106831707B (zh) | 作为c-Met激酶抑制剂的苯并杂环类衍生物及其医疗用途 | |
WO2021250025A1 (en) | Small-molecule inhibitors of the frs2-fgfr interaction and their use in medicine, in the prevention and treatment of cancer | |
CN104829671A (zh) | No供体型的吉西他滨/fta/呋咱缀合物及制备方法和用途 | |
KR20190110581A (ko) | 암 치료 | |
JP6461088B2 (ja) | 高分子化カンプトテシン誘導体及び高分子化hsp90阻害剤誘導体を含む医薬組成物 | |
WO2019217933A1 (en) | Inhibitors of the ras oncoprotein, methods of making and methods of use thereof | |
Gao et al. | Design, synthesis and biological evaluation of novel histone deacetylase (HDAC) inhibitors derived from β-elemene scaffold | |
WO2023105008A1 (en) | Small-molecule inhibitors of the frs2-fgfr interaction | |
CN104844526A (zh) | 一种4,6-嘧啶二胺类化合物及其制备方法和应用 | |
Xu et al. | Advances in cancer chemotherapeutic drug research in China | |
CN105541696B (zh) | 一种抗肿瘤的化合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210504 |
|
CF01 | Termination of patent right due to non-payment of annual fee |